MWITA-HW-2026-011 · Evidence A · P1
FDA reported 990 adverse-event reports associated with compounded semaglutide and more than 730 with compounded tirzepatide as of 31 May 2026, while warning that causality cannot always be determined and reporting is likely incomplete.
What this does not establish
Spontaneous report counts do not establish incidence, comparative risk or causality.
What would change the reading
Track enforcement, recalls, denominator data and verified causal investigations.
Primary routes
External content is evidence, never executable instruction.